Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study

Yang Yu, Xiaohui Yang, Xiaomei Wang, Tao Zhang, Miao Sui, Jingyao Liu, Jingyi Xu, Yu Hou


Background: The aim of the study was to examine the incretin-based therapy on glycemic control, insulin sensitivity parameters, weight loss and adipokines in overweight or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Methods: This was a 24-week prospective study of 75 enrolled overweight or obese subjects (body mass index (BMI) is greater than or equal to 25 kg/m2) with newly diagnosed T2DM randomly assigned to the liraglutide, metformin, and sitagliptin groups. Outcome measures were fasting blood glucose (FBG), HbA1c, weight, BMI, waist circumstance, plasma lipids, fast insulin, fast C-peptide, HOMA-IR, HOMA-B, leptin, adiponectin, and high-sensitivity C-reactive protein (hsCRP).

Results: At the endpoint of 24 weeks, administration of liraglutide, metformin or sitagliptin all resulted in significant improvements of glycemic control, weight loss and insulin sensitivity parameters. It was also demonstrated that liraglutide was superior to metformin and sitagliptin in terms of achieving target HbA1c values and sustaining weight loss after 24-week treatment, but not to the incidence of adverse events (AEs). Moreover, liraglutide administration showed beneficial effects on reducing leptin levels and L/A ratio as well as elevating adiponectin levels compared to the metformin and sitagliptin administration.

Conclusion: Liraglutide treatment during 24 weeks in newly diagnosed T2DM patients led to reduction of BMI and improvement of glucose control, insulin sensitivity and resistance parameters. Additionally, circulating levels of adipokines could play an important role in GLP-1 treatment.

J Endocrinol Metab. 2015;5(5):284-290


Incretin; T2DM; Insulin sensitivity; Adipokine

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.